haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Company profile
Ticker
HAE
Exchange
Website
CEO
Christopher Simon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
5D Information Management, Inc. • Arryx, Inc. • Cardiva Medical, Inc. • Enicor GmbH • Global Med Technologies, Inc. • Haemonetics (Hong Kong) Limited • Haemonetics Asia Incorporated • Haemonetics Asia UK Ltd. • Haemonetics Australia PTY Ltd. • Haemonetics BV ...
IRS number
42882273
HAE stock data
Latest filings (excl ownership)
8-K
Haemonetics Corporation Completes Acquisition of Attune Medical
1 Apr 24
8-K
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
5 Mar 24
10-Q
2024 Q3
Quarterly report
8 Feb 24
8-K
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2024 Results; Updates Fiscal 2024 Guidance
8 Feb 24
8-K
Other Events
12 Dec 23
10-Q
2024 Q2
Quarterly report
2 Nov 23
8-K
Haemonetics Reports Second Quarter and First Half Fiscal 2024 Results; Updates Fiscal 2024 Guidance
2 Nov 23
8-K/A
Financial Statements and Exhibits
12 Oct 23
8-K
Entry into a Material Definitive Agreement
10 Oct 23
S-8
Registration of securities for employees
11 Aug 23
Transcripts
HAE
Earnings call transcript
2024 Q3
8 Feb 24
HAE
Earnings call transcript
2024 Q2
2 Nov 23
HAE
Earnings call transcript
2024 Q1
8 Aug 23
HAE
Earnings call transcript
2023 Q4
11 May 23
HAE
Earnings call transcript
2023 Q3
7 Feb 23
HAE
Earnings call transcript
2023 Q2
7 Nov 22
HAE
Earnings call transcript
2023 Q1
10 Aug 22
HAE
Earnings call transcript
2022 Q4
10 May 22
HAE
Earnings call transcript
2022 Q3
8 Feb 22
HAE
Earnings call transcript
2022 Q2
9 Nov 21
Latest ownership filings
4
Anila Lingamneni
17 Apr 24
4
Christopher Simon,
13 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Neuberger Berman Group LLC
13 Feb 24
SC 13G/A
Capital Research Global Investors
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
4
Roy Galvin
3 Nov 23
4
Michelle L Basil
24 Oct 23
4
Stewart W Strong
24 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 23 | Apr 22 | Apr 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 292 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Anila Lingamneni | Common Stock | Payment of exercise | Dispose F | No | No | 84.88 | 184 | 15.62 k | 14,311 |
11 Mar 24 | Simon, Christopher | Common Stock | Gift | Dispose G | No | No | 0 | 38,900 | 0.00 | 257,546 |
1 Nov 23 | Roy Galvin | Common Stock | Payment of exercise | Dispose F | No | No | 86.39 | 160 | 13.82 k | 4,595 |
20 Oct 23 | Stewart W Strong | Common Stock | Payment of exercise | Dispose F | No | No | 89.05 | 120 | 10.69 k | 16,101 |
20 Oct 23 | Basil Michelle L | Common Stock | Payment of exercise | Dispose F | No | No | 89.05 | 197 | 17.54 k | 32,272 |
News
Barrington Research Maintains Outperform on Haemonetics, Maintains $105 Price Target
12 Apr 24
Haemonetics Received 510(k) Clearance From FDA For TEG 6s Hemostasis Analyzer System Global Hemostasis-HN Assay Cartridge
4 Apr 24
Barrington Research Reiterates Outperform on Haemonetics, Maintains $105 Price Target
13 Feb 24
Haemonetics Q3 Adjusted EPS $1.04 Beats $0.94 Estimate, Sales $336.25M Beat $320.29M Estimate
8 Feb 24
Earnings Scheduled For February 8, 2024
8 Feb 24
Press releases
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024
10 Apr 24
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
4 Apr 24
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
4 Apr 24
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
5 Mar 24
Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference
21 Feb 24